- Report
- January 2022
- 148 Pages
Global
From €3777EUR$4,250USD£3,270GBP
From €3777EUR$4,250USD£3,270GBP
- Report
- March 2018
- 102 Pages
Global
From €2444EUR$2,750USD£2,116GBP
- Report
- November 2024
- 100 Pages
Global
From €3500EUR$4,218USD£3,136GBP
- Report
- March 2024
- 138 Pages
Global
From €3500EUR$4,218USD£3,136GBP
- Report
- June 2023
- 104 Pages
Global
From €3500EUR$4,218USD£3,136GBP
- Report
- June 2023
- 119 Pages
Global
From €3500EUR$4,218USD£3,136GBP
- Report
- May 2023
- 91 Pages
Global
From €3500EUR$4,218USD£3,136GBP
- Report
- April 2025
- 275 Pages
China
From €3555EUR$4,000USD£3,078GBP
- Report
- March 2025
- 214 Pages
China
From €3555EUR$4,000USD£3,078GBP
- Report
- March 2025
- 65 Pages
China
From €1600EUR$1,800USD£1,385GBP
- Report
- September 2024
- 121 Pages
China
From €1600EUR$1,800USD£1,385GBP
- Report
- March 2024
- 132 Pages
Global
From €844EUR$950USD£731GBP
The Anticancer Agent market is a segment of the Healthcare Services industry that focuses on the development and distribution of drugs and treatments for cancer. These agents are designed to target and destroy cancer cells while minimizing the damage to healthy cells. They can be administered orally, intravenously, or topically, depending on the type of cancer and the patient's individual needs. Anticancer agents are used in combination with other treatments such as radiation and chemotherapy to provide the best possible outcome for the patient.
The Anticancer Agent market is highly competitive, with many companies vying for market share. Companies in this market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more
